EDAP TMS SA (EDAP) plummets as FDA nixes drug

EDAP TMS SA (NASDAQ: EDAP) fell 42.7% to $1.96 following the FDA Panel rejection of Ablatherm-HIFU for the treatment of prostate cancer. Share volume was 485,000, compared to an all-day average of 117,000